Table 1.
Median age, y (range) | 66 (44– 78) |
Female, n % | 8 (45%) |
Median prior lines of therapy, n (range) | 5 (1–11) |
Prior Daratumumab exposure, n % | 8 (45%) |
Prior ASCT, n % | 15 (83%) |
Median time (years) since initial diagnosis of MM (range), y (range) | 4 (1–9) |
Footnote: the number above refer to all 18 patients who received treatment with SId